"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...

Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

AbbVie has expanded the availability of SKYRIZI in Canada for ulcerative colitis, strengthening its presence in the ...

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its ...

Moderna (NASDAQ:MRNA) is targeting market approval of a personalized vaccine the company is developing with Merck (NYSE:MRK) ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...